Sign in

    Sepehr Manochehry

    Research Analyst at Eight Capital

    Sepehr Manochehry is an Equity Research Analyst at Eight Capital specializing in healthcare, biotech, and life sciences with direct coverage of companies such as CareRx Corporation and Cybin Inc. He regularly participates in earnings calls for these firms and is recognized for his analytical contributions within the Canadian healthcare investment community. Manochehry began his career in healthcare business development and consulting, holds a PhD, and previously served as Vice President for Healthcare & Biotech investment banking at Clariti Strategic Advisors before joining Eight Capital. He maintains relevant securities industry credentials and is known for his expertise in life sciences innovation and investment analysis.

    Sepehr Manochehry's questions to CYBIN (CYBN) leadership

    Sepehr Manochehry's questions to CYBIN (CYBN) leadership • Q3 2022

    Question

    Sepehr Manochehry of Eight Capital questioned the design of the CYB003 trial, asking about the type of placebo to be used, blinding controls, and patient inclusion criteria. He also asked if there was potential for a post-hoc analysis for Alcohol Use Disorder (AUD) and inquired about the status of any pre-IND meetings with the FDA.

    Answer

    CEO Douglas Drysdale clarified that the trial will use a true placebo and will be fully blinded. A key aspect of the inclusion criteria is that patients with moderate to severe depression will remain on their SSRIs, positioning CYB003 as an adjunctive therapy. He noted that MDD and AUD are distinct populations, precluding a post-hoc analysis. He also confirmed that while they have met with other regulators, they do not expect a pre-IND meeting with the FDA before the Q2 submission.

    Ask Fintool Equity Research AI